Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Recurrent or Metastatic Breast Cancer
Interventions: DRUG: Oral paclitaxel|DRUG: Paclitaxel injection
Sponsor: Daehwa Pharmaceutical Co., Ltd.